Tags: Neuroprotection

announcements

January 8, 2018

$1.8 Million in New Funding Supports Clinical Stage Treatments

The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.

blog

January 2, 2018

Top Five Alzheimer’s Advances in 2017

Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.

blog

November 28, 2017

Closing in on a Cure: Dr. Roberta Diaz Brinton and Allopregnanolone

With funding from the ADDF since 2004, Dr. Roberta Diaz Brinton has developed what may become the first ever regenerative treatment for Alzheimer's disease.

announcements

September 13, 2017

18th Annual Conference on Alzheimer’s Drug Discovery Showcases Non-Amyloid Research

Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.

announcements

April 13, 2017

ADDF Funding Advances M3 Biotechnology Toward Clinical Trials

Our new investment in M3 Biotechnology is advancing its drug program toward clinical trials

announcements

March 7, 2017

$4 Million in New Grants Support Several First-in-Class Dementia Treatments

We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

blog

February 21, 2017

Closing in on a Cure: Dr. Michela Gallagher and AGB101

Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.

announcements

January 9, 2017

$2.5 Million in New Grants Advance Clinical Trials of Alzheimer’s Treatments

We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.  

blog

December 15, 2016

Closing in on a Cure: Dr. Frank Longo and C-31

We have supported over 20% of all Alzheimer's treatments currently in clinical trials. One of the most promising is C-31, developed by Frank Longo, MD, PhD.

announcements

November 8, 2016

$1.5 Million in New Grant Funding for Promising Treatments

The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million. 

announcements

September 12, 2016

Three New Grants Support Promising Treatments for Alzheimer’s Disease

The ADDF awarded three new grants in July and August for potential new treatments for Alzheimer's and other dementias. 

announcements

July 7, 2016

Five New Grants Fund Promising Treatments & Biomarkers

The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.

announcements

May 10, 2016

Ten New Grants Support Alzheimer’s Drug Discovery and Biomarker Development

The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.

blog

March 1, 2016

Dr. Carmela Abraham Founds New Biotech

With support from the ADDF, Carmela Abraham, PhD recently founded Klogene to accelerate the development of a new class of drugs to combat Alzheimer’s disease.

blog

February 25, 2016

Alzheimer’s Drug Featured in Time Was Made Possible by the ADDF

Grantee Dr. Frank Longo's promising new drug to treat Alzheimer's is on the cover of Time magazine.

announcements

January 5, 2016

Five New Research Grants Support Clinical and Early-Stage Programs

Funded Researchers are pursuing diverse targets to treat Alzheimer's disease.

announcements

November 4, 2015

New Grant Supports AlzeCure’s Work on Neurorestorative Drug

AlzeCure Foundation announced today that it has been awarded a grant from the ADDF to support the further development of its small molecule neurorestorative project.

announcements

September 16, 2015

Dr. Frank Longo Wins Inaugural Melvin R. Goodes Prize

Dr. Longo's pioneering approach may soon lead to new disease modifying drugs.

blog

February 3, 2015

Early-Stage Dementia Treatment Headed to Phase 3 Clinical Trial

ADDF-funded researchers are preparing for a phase 3 trial of what could become the first drug approved for mild cognitive impairment. 

announcements

January 28, 2015

New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial

The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.

blog

September 24, 2014

New Drug Targets Are Highlight of Alzheimer’s Conference

Presenters at our recent conference shared exciting progress on new Alzheimer's drug targets and biomarkers. 

announcements

March 6, 2013

Alzheimer’s Drug Discovery Foundation Awards Grant To Cohbar To Develop A Novel Peptide Therapeutic

The ADDF has awarded $205,260 in funding to CohBar Inc. to develop a mitochondrial peptide, which has been shown to have neuroprotective effects.